TEMOZOLOMIDE & BCNU FOR ANAPLASTIC GLIOMAS

替莫唑胺

• 批准号: 6263693
• 负责人: HARRY S GREENBERG
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263693
• 关键词: astrocytoma; carmustine; clinical research; combination chemotherapy; glioma; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; temozolomide

A phase II multicenter North American Brain Tumor Board Consortium trial to treat malignant astrocytomas with the combination of IV BCNU and oral temozolomide. The mechanism of denovo drug-resistance for these drugs is high levels of the enzyme O 6 alkylguanine transferase. BCNU will be used to deplete this enzyme with the theory that temozolomide will be more effective with lower cellular levels of the enzyme. There will be two patient groups studied 1.) recurrent glioblastoma after primary treatment failure (surgery, radiation and chemotherapy) and 2.) anaplastic gliomas and mixed anaplastic gliomas following surgery without prior radiation therapy.

北美脑肿瘤委员会联盟进行的一项 II 期多中心试验，采用 IV BCNU 和口服替莫唑胺联合治疗恶性星形细胞瘤。 这些药物的从头耐药机制是高水平的O 6 烷基鸟嘌呤转移酶。 BCNU 将用于消耗这种酶，其理论是，当该酶的细胞水平较低时，替莫唑胺会更有效。 将研究两个患者组：1.) 初次治疗失败（手术、放疗和化疗）后复发的胶质母细胞瘤，以及 2.) 手术后未经事先放疗的间变性胶质瘤和混合性间变性胶质瘤。